2022 World Conference on Lung Cancer (ePosters)-EP02.01-006. Advances in the Treatment of Postoperative Recurrence of Non-Small Cell Lung Cancer and Their Real-World Impact on Survival

EP02.01-006. Advances in the Treatment of Postoperative Recurrence of Non-Small Cell Lung Cancer and Their Real-World Impact on Survival

Back to course

Pdf Summary

A recent study conducted in Japan examined the impact of targeted therapy drugs known as tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) on the survival of patients with postoperative recurrence of non-small cell lung cancer (NSCLC). The study's findings suggest that these therapies can greatly benefit patients with recurrent NSCLC.<br /><br />The retrospective study looked at data from patients who underwent lobectomy or more extensive surgery for NSCLC between 2008 and 2018. The researchers analyzed the use of TKIs and ICIs in the treatment of post-recurrence NSCLC and assessed their impact on survival.<br /><br />The results showed that the use of TKIs remained stable over the years, while the use of ICIs increased in parallel with improved survival rates. The study found that the use of TKIs and ICIs was associated with a significant improvement in 2-year overall survival after recurrence of NSCLC.<br /><br />The study also identified predictors of post-recurrence survival, which can help guide treatment decisions for patients with recurrent NSCLC. These predictors include mutation status, with patients who had EGFR or ALK mutations experiencing better survival outcomes.<br /><br />The study highlights the importance of monitoring the impact of evolving treatments, such as TKIs and ICIs, on post-recurrent NSCLC. The findings provide encouraging evidence that targeted therapies and immunotherapies can improve survival for patients with recurrent NSCLC.<br /><br />It is worth noting that this study was a single-center retrospective analysis, and further research is needed to confirm these findings. Nonetheless, the results suggest that advancements in the treatment of postoperative recurrence of NSCLC have the potential to significantly impact patient outcomes.

Asset Subtitle

Kohei Hashimoto

Meta Tag

Speaker Kohei Hashimoto

Topic Early Stage Non-small Cell Lung Cancer - Biomarkers

Keywords

study

Japan

targeted therapy drugs

tyrosine kinase inhibitors

immune checkpoint inhibitors

survival

patients

non-small cell lung cancer

retrospective study

lobectomy